This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Why Akebia Therapeutics (AKBA) Stock Soared Today

Stocks in this article: AKBA

NEW YORK (TheStreet) -- Akebia Therapeutics (AKBA) soared more than 25% on Monday on high volume after UBS initiated coverage on the biopharmaceutical company with a "buy" rating and $28 price target.

"Akebia Therapeutics is a clinical-stage biotech company that we believe is well positioned to produce a treatment for anemia that is potentially safer than current products, which have black box warnings for increased death and cardiovascular events but generated >$6bn in sales in 2013," UBS wrote in a research note. "The company's wholly-owned once-daily oral HIF-PH inhibitor AKB-6548 is in Phase-2b for anemia of chronic kidney disease (CKD). Akebia's second candidate, AKB-6899, is in preclinical studies for oncology."

The Cambridge, Mass.-based drug maker went public in March. UBS also outlined the following points to support its "buy" rating:

[1] HIF activators could become the standard of care in the anemia market if they are approved without the same black box warnings as injectable erythropoiesis-stimulating agents (ESAs) and hence are perceived to be safer than ESAs. The safety of AKB-6548 is supported by clinical and pre-clinical data and the highaltitude literature, which shows no untoward effect of HIF activation. [2] We see blockbuster potential for '6548 if it is found to be safe and effective. It would be second to market but would be well-positioned among competitors due to attractive once-daily dosing and still be ahead of two additional competitors in a multi-billion dollar market. [3] Near term ph2b data (4Q14e) could drive a valuation step-up in AKBA shares. [4] Management has extensive knowledge and experience executing in the CKD segment.

The stock closed up 25.39% to $21.14, a $4.28 increase from its previous close of $16.86. More than 2.9 million hares changed hands, well above the average volume of 423,041. The stock held a range of $17.07 to $23.32 for the day and holds a one-year range of $16.41 to $28.50.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. AKBA Chart

AKBA data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs